Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukemia

Normalized, scaled metabolite abundance data from an experiment involving profiling of diagnostic bone marrow plasma samples from N=155 children with acute lymphoblastic leukemia. Patients were diagnosed at Texas Children's Hospital between 2007-15 and treated on or according to Children's Oncology Group frontline ALL protocols. Metabolomics data were generated from 2017-18 using the Metabolon Global Metabolomics platform. Missing values have been imputed with the minimum. Data are annotated with sex; race/ethnicity; height, weight, age, and white blood cell count at diagnosis; NCI risk group; cytogenetic category; central carbon metabolism cluster membership derived from metabolite set enrichment analysis and hierarchical clustering analyses; end-induction minimal residual disease (MRD) status; and relapse status if known. Data are divided into a discovery (N=93) and replication (N=62) partition.

本数据集为一项针对155例急性淋巴细胞白血病（Acute Lymphoblastic Leukemia, ALL）患儿的诊断性骨髓血浆样本开展代谢谱分析的实验所获得的经归一化、标准化处理的代谢物丰度数据。所有患儿均于2007年至2015年间在德克萨斯儿童医院确诊，并按照儿童肿瘤协作组（Children's Oncology Group, COG）一线ALL治疗方案接受治疗。代谢组学数据于2017年至2018年间通过Metabolon全球代谢组学平台生成，缺失值已采用最小值插补法完成填充。数据集附带以下注释信息：患儿性别、种族/族裔、确诊时的身高、体重、年龄与白细胞计数、美国国家癌症研究所（National Cancer Institute, NCI）风险分组、细胞遗传学分类、通过代谢物集富集分析（Metabolite Set Enrichment Analysis）与层次聚类（Hierarchical Clustering）分析得到的中心碳代谢簇归属、诱导治疗结束时的微小残留病（Minimal Residual Disease, MRD）状态，以及已知情况下的复发状态。数据集被划分为发现队列（N=93）与验证队列（N=62）两个子集。